TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.

ABSTRACT:

Purpose

Fulvestrant is an estrogen receptor (ER) antagonist and an approved treatment for metastatic estrogen receptor-positive (ER⁺) breast cancer. With the exception of ER levels, there are no established predictive biomarkers of response to single-agent fulvestrant. We attempted to identify a gene signature of response to fulvestrant in advanced breast cancer.

Experimental design

Primary tumor samples from 134 patients enrolled in the phase III CONFIRM study of patients with metastatic ER⁺ breast cancer comparing treatment with either 250 mg or 500 mg fulvestrant were collected for genome-wide transcriptomic analysis. Gene expression profiling was performed using Affymetrix microarrays. An exploratory analysis was performed to identify biologic pathw

SUBMITTER: Jeselsohn R 

PROVIDER: S-EPMC5124409 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature